PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Real-World SCFF vs Intestinal Levodopa: High Dropout, Clinician-Patient Mismatch

foslevodopa-foscarbidopalevodopa-carbidopa intestinal gellevodopa-entacapone-carbidopa intestinal geldopaminergic agentsParkinson's diseasemotor fluctuationsdevice-assisted therapyretrospective observational studyreal-world evidenceadverse events Neurology / Neuropharmacology

Background Information

High dropout rates challenge the promise of novel PD therapies.

Subcutaneous foslevodopa-foscarbidopa (SCFF) is a novel non-surgical option for advanced Parkinson's disease, but lacks real-world data. SCFF showed real-world efficacy, but 33% withdrew within 4 weeks; patient-clinician efficacy perceptions differed significantly. The findings highlight the need for systematic management guidelines for SCFF amid high dropout and perception discrepancies. SCFF may control motor fluctuations in advanced PD, but structured management is needed due to high early dropout rates.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Hartig J, Sitzmann L, Hartenstein D, Labisch M, Ip CW, Volkmann J, Daniels C

Citation: Hartig J, Sitzmann L, Hartenstein D, et al. Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real-World, Monocentric, Observational Study and Critical Review. Movement disorders clinical practice. 2026;13(7):1662-1672. doi:10.1002/mdc3.70557

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.